干扰素γ与肝纤维化治疗
被引量:2
Interferon gamma and the treatment of hepatic fibrosis
摘要
干扰素γ(IFNγ)具有很强的抗肝纤维化作用,近年来IFNγ治疗肝纤维化的临床和基础研究已有很大进展,现就此作一综述。
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2008年第12期955-957,共3页
Chinese Journal of Hepatology
关键词
干扰素Γ
肝纤维化
治疗
Interferon-gamma
Liver fibrosis
Treatment
参考文献15
-
1Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol, 2005, 3: 819-828.
-
2Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat, 2006, 13: 322-328.
-
3Pockros P J, Jeffers L, Afdhal N, et al. Final results of a doubleblind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology, 2007, 45: 569-578.
-
4Soza A, Heller T, Ghany M, et al. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol, 2005, 43:67-71.
-
5Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology, 2003, 38: 1449-1457.
-
6Chevillard C, Moukoko CE, Elwali NE, et al. IFN-gamma polymorphi sms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). J Immunol, 2003, 171: 5596-5601.
-
7Booth M, Mwatha JK, Joseph S, et al. Pefiportal fibrosis in human Sehistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Irnmunol, 2004, 172: 1295-1303.
-
8Dessein A, Kouriba B, Eboumbou C, et al. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev, 2004, 201: 180- 190.
-
9Dessein AJ, Hillaire D, Elwali NE, et al. Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet, 1999, 65: 709-721.
-
10Jeong Wl, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology, 2008, 134: 248-258.
同被引文献39
-
1赵红宇,李文斌.灵芝孢子粉抗肝纤维化作用的实验研究[J].中国实用医药,2007,2(5):12-14. 被引量:6
-
2李兵顺,阎文昭,刘金星,甄真,孔丽,刘芳.纤维化肝组织转化生长因子β1表达水平与肝纤维化程度的关系[J].中华传染病杂志,2005,23(2):112-114. 被引量:19
-
3何延专,覃后继,黄重敏,周耀南,黄其文,陆春雷.舒肝宁联合促肝细胞生长素治疗慢性乙型肝炎临床观察[J].右江民族医学院学报,2006,28(3):365-367. 被引量:2
-
4王伟雅,李飞,贾雪梅,王红,李翠英,金亮.干扰素α和γ抗小鼠日本血吸虫病肝纤维化疗效对比[J].中华肝脏病杂志,2007,15(6):467-468. 被引量:2
-
5陈明泉,李谦,张琼华,张玉杰,施光峰.舒肝宁注射液治疗急慢性病毒性肝炎的临床疗效观察[J].肝脏,2007,12(3):194-196. 被引量:23
-
6Cassiman D,Lihbrecht L,Desmet V. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers[J].Journal of Hepatology,2002.209.
-
7Pol S,Carnot F,Nalpas B. Reversihility of hepatitis C virus-related cirrhosis[J].Human Pathology,2004,(01):107.doi:10.1016/j.humpath.2003.08.012.
-
8Xu MD,Li WQ,Yu HY. Research on microRNA in liver disease and hepatic fibrosis[J].Ocular Immunology and Inflammation,2011,(01):65-67.
-
9Mehal W,Imaeda A.Cell death and fibrogenesis[J].Semin Liver Dis,2010,30(3):226-231.
-
10Puche JE,Saiman Y,Friedman SL.Hepatic stellate cells and liver fibrosis[J].Compr Physiol,2013,3(4):1473-1492.
引证文献2
-
1朱永辉,邓维成,何永康,李岳生,荆群山,杨米佳,朱剑君,李俊,郑娜,陶江,杨建仁.舒肝宁注射液对晚期血吸虫病肝纤维化患者血清转化生长因子β_1、γ-干扰素水平的影响[J].中国老年学杂志,2012,32(8):1592-1593. 被引量:11
-
2梁潆丹,李晖,侯艳锋,胥展志,江婷.NK细胞与肝纤维化的相关性研究进展[J].免疫学杂志,2015,31(11):1005-1008. 被引量:4
二级引证文献15
-
1刘敏.舒肝宁注射液对晚期血吸虫病肝纤维化患者HA,Ⅳ-C,LN,PC-Ⅲ水平的影响[J].智慧健康,2023,9(10):101-104. 被引量:1
-
2来如意,何永康,邓维成,刘爱忠,荆群山.腹水型晚期血吸虫病治疗方法研究进展[J].热带医学杂志,2012,12(12):1536-1538. 被引量:4
-
3张素媛,刘梅娟,范杰斐.肝纤维化的血清学检测指标特点分析[J].按摩与康复医学,2014,5(4):188-189. 被引量:1
-
4姜迎华,吴慧芳,王吉平.上海市金山区张堰镇晚期血吸虫患者生存的相关因素分析[J].实用预防医学,2014,21(7):822-824. 被引量:2
-
5黎晓琴.扶正化瘀胶囊治疗日本血吸虫病肝纤维化的效果[J].中国当代医药,2015,22(20):136-138. 被引量:3
-
6张瑾.舒肝宁注射液对顺铂中毒小鼠肝脏损伤的保护作用[J].中国药房,2016,27(7):920-922. 被引量:18
-
7梁海雄.舒肝宁注射液治疗病毒性肝炎研究进展[J].大众科技,2015,17(12):62-63. 被引量:3
-
8钟兴明,苗竹林,崔蓉,杨宁,王一峰,王小兰,韦相才.PCOS不孕患者性激素与外周血NK细胞活性的相关性研究[J].免疫学杂志,2016,32(9):800-803. 被引量:9
-
9朱永辉,赵正元,邓维成.晚期血吸虫病多学科综合治疗的价值与评价[J].中国血吸虫病防治杂志,2017,29(3):267-272. 被引量:8
-
10唐秀斌,林礼务,陈志奎,张秀娟,钱清富,谢丽红,薛恩生.剪切波弹性成像评价γ-干扰素对兔肝纤维化治疗效果的实验研究[J].临床超声医学杂志,2019,21(11):801-806. 被引量:2
-
1来丽娜,方步武.肝纤维化治疗的探索[J].中西医结合肝病杂志,2003,13(6):381-383. 被引量:5
-
2贾继东,王宝恩.肝纤维化治疗的实验及临床研究[J].新医学,1993,24(9):454-455. 被引量:5
-
3刘虹.安络化纤丸抗纤维化的疗效观察[J].传染病信息,2006,19(1):40-40. 被引量:1
-
4袁喆.安络化纤丸治疗慢性乙型肝炎肝纤维化临床疗效观察[J].传染病信息,2006,19(2):87-87. 被引量:5
-
5陈以甦,林彩文.血府逐瘀胶囊治疗非酒精性脂肪性肝病临床疗效分析[J].北京中医药,2013,32(5):379-380. 被引量:1
-
6韩秋玉,韩爱琴,陈林.秋水仙碱治疗早期肝硬化的疗效观察[J].现代医药卫生,2005,21(24):3367-3368. 被引量:4
-
7郭子林,张丽芳,刘玉庆,李淑玲,时彩玲,刘桂兰.秋水仙碱抗肝纤维化疗效观察[J].济宁医学院学报,2000,23(3):41-41. 被引量:6
-
8姚希贤.肝纤维化治疗现状与进展[J].现代消化及介入诊疗,2003,8(3):177-180.
-
9叶俊茂.丹参在慢性乙型肝炎治疗中抗肝纤维化疗效观察[J].宁波医学,1996,8(3):170-170.
-
10宋方剂,栗华.苦参素联合复方丹参治疗肝纤维化的临床观察[J].中华腹部疾病杂志,2003,3(7):491-492.